Viatris (VTRS) is in the midst of a securities fraud lawsuit and stockholders suffering big losses are urged to contact various law firms representing the class action. Meanwhile, Goldman Sachs has initiated coverage on Viatris with a neutral rating and recommendation, putting the company under financial scrutiny. However, Viatris also reported exciting developments with
positive Phase 3 trial results for their breakthrough drug, which aims to help those with night driving vision disturbances. These developments, alongside reports of the company meeting its quarter and full year financial expectations for 2024, indicate a potential upward trend in their financial performance. Viatris also announced several key achievements, including agreements on targeted divestitures, appointment of a new CEO, Scott A. Smith, and the positive top-line results from the LYNX-2 trial of MR-142, a drug designed for patients with visual disturbances. Lastly, the company published its
sustainability report for 2022, showcasing progress on facilitating sustainable access to medications.
Viatris VTRS News Analytics from Mon, 27 Feb 2023 08:00:00 GMT to Sat, 07 Jun 2025 16:24:29 GMT -
Rating 2
- Innovation 3
- Information 5
- Rumor -2
